Clinical Cardiology 1402 - Clinical Cardiology Alert - Feb 01, 2010

Target Audience:

This activity is intended for the cardiologist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Physician Editor
Michael H. Crawford, MD
Professor of Medicine
Chief of Cardiology
University of California
San Francisco

Editorial Board Members
John P. DiMarco, MD, PhD
Professor of Medicine
Division of Cardiology
University of Virginia
Charlottesville

Jonathan Abrams, MD
Professor of Medicine
Division of Cardiology
University of New Mexico
Albuquerque

Andrew J. Boyle, MBBS, PhD
Assistant Professor of Medicine
Interventional Cardiology
University of California
San Francisco

Peer Reviewer
Ethan Weiss, MD
Assistant Professor of Medicine
Division of Cardiology and CVRI
University of California, San Francisco

Subjects:

  • Contraindicated Medications Increase Risk of PCI in Dialysis Patients
  • Intensive Lipid Lowering in ACS Patients Undergoing PCI
  • Niacin and Vascular Diseases
  • Off-pump Coronary Bypass Surgery vs. Traditional CABG — Is There a Winner?
  • Value of VT Ablation Prior to ICD Placement
  • FDA and Medical Devices

Objectives:

  • to present the latest information regarding diagnosis and treatment of cardiac disease
  • to discuss the pros and cons of these interventions, as well as possible complications
  • to discuss the pros, cons, and cost-effectiveness of new and traditional diagnostic tests
  • to present current data regarding outpatient care of cardiac patients

Financial Disclosure:

Clinical Cardiology Alert’s physician editor, Michael H. Crawford, MD, is on the speaker’s bureau for Pfizer. Editorial board member Jonathan Abrams, MD serves on the speaker's bureau for Merck, Pfizer, and Parke-Davis. John P. DiMarco, MD, PhD is a consultant for Novartis, and does research for Medtronic and Guidant. Editorial board member Andrew J. Boyle, MBBS, PhD, and peer reviewer, Ethan Weiss, MD, reports no consultant, stockholder, speaker’s bureau, or other financial relationship with any company related to this field of study.

Copyright 2010 AHC Media. All rights reserved.